Clinical and Microbiologic Characteristics of Clostridium difficile Infection Caused by Binary Toxin Producing Strain in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Binary toxin-producing Clostridium difficile infections (CDI) are known to be more severe and to cause higher case fatality rates than those by binary toxin-negative isolates. There has been few data of binary toxin-producing CDI in Korea. Objective of the study is to characterize clinical and microbiological trait of CDI cause by binary-toxin producing isolates in Korea. Materials and Methods: From September 2008 through January 2010, clinical characteristics, medication history and treatment outcome of all the CDI patients were collected prospectively. Toxin characterization, PCR ribotyping and antibiotic susceptibility were performed with the stool isolates of C. difficile . Results: During the period, CDI caused by 11binary toxin-producing isolates and 105 toxin A & toxin B-positive binary toxin-negative isolates were identified. Comparing the disease severity and clinical findings between two groups, leukocytosis and mucoid stool were more frequently observed in patients with binary toxin-positive isolates (OR: 5.2, 95% CI: 1.1 to 25.4, P = 0.043; OR: 7.6, 95% CI: 1.6 to 35.6, P = 0.010, respectively), but clinical outcome of 2 groups did not show any difference. For the risk factors for acquisition of binary toxin-positive isolates, previous use of glycopeptides was the significant risk factor (OR: 6.2, 95% CI: 1.4 to 28.6, P = 0.019), but use of probiotics worked as an inhibitory factor (OR: 0.1, 95% CI: 0.0 to 0.8; P = 0.026). PCR ribotypes of binary toxinproducing C. difficile showed variable patterns: ribotype 130, 4 isolates; 027, 3 isolates; 267 and 122, 1 each isolate and unidentified C1, 2 isolates. All 11 binary toxin-positive isolates were highly susceptible to clindamycin, moxifloxacin, metronidazole, vancomycin and piperacillin-tazobactam, however, 1 of 11 of the isolates was resistant to rifaximin. Conclusions: Binary toxin-producing C. difficile infection was not common in Korea and those isolates showed diverse PCR ribotypes with high susceptibility to antimicrobial agents. Glycopeptide use was a risk factor for CDI by those isolates.
Abstract
Background: Binary toxin-producing Clostridium difficile infections (CDI) are known to be more severe and to cause higher case fatality rates than those by binary toxin-negative isolates. There has been few data of binary toxin-producing CDI in Korea. Objective of the study is to characterize clinical and microbiological trait of CDI cause by binary-toxin producing isolates in Korea. Materials and Methods: From September 2008 through January 2010, clinical characteristics, medication history and treatment outcome of all the CDI patients were collected prospectively. Toxin characterization, PCR ribotyping and antibiotic susceptibility were performed with the stool isolates of C. difficile . Results: During the period, CDI caused by 11binary toxin-producing isolates and 105 toxin A & toxin B-positive binary toxin-negative isolates were identified. Comparing the disease severity and clinical findings between two groups, leukocytosis and mucoid stool were more frequently observed in patients with binary toxin-positive isolates (OR: 5.2, 95% CI: 1.1 to 25.4, P = 0.043; OR: 7.6, 95% CI: 1.6 to 35.6, P = 0.010, respectively), but clinical outcome of 2 groups did not show any difference. For the risk factors for acquisition of binary toxin-positive isolates, previous use of glycopeptides was the significant risk factor (OR: 6.2, 95% CI: 1.4 to 28.6, P = 0.019), but use of probiotics worked as an inhibitory factor (OR: 0.1, 95% CI: 0.0 to 0.8; P = 0.026). PCR ribotypes of binary toxinproducing C. difficile showed variable patterns: ribotype 130, 4 isolates; 027, 3 isolates; 267 and 122, 1 each isolate and unidentified C1, 2 isolates. All 11 binary toxin-positive isolates were highly susceptible to clindamycin, moxifloxacin, metronidazole, vancomycin and piperacillin-tazobactam, however, 1 of 11 of the isolates was resistant to rifaximin. Conclusions: Binary toxin-producing C. difficile infection was not common in Korea and those isolates showed diverse PCR ribotypes with high susceptibility to antimicrobial agents. Glycopeptide use was a risk factor for CDI by those isolates.
참고문헌 (29)
- Hubert B, "A portrait of the geographicdissemination of the Clostridium difficile NorthAmerican pulsed-field type 1 strain and the epidemiologyof C. difficile-associated disease in Quebec", Clin InfectDis, 44, pp.238~244 (2007)
- Cheknis AK, "Distribution of Clostridium difficile strainsfrom a North American, European and Australian trial oftreatment for C. difficile infections: 2005-2007", Anaerobe, 15, pp.23~233 (2009)
- Kim J, "Epidemiology of Clostridiumdifficile infections in a tertiary-care hospital in Korea", Clin Microbiol Infect, 21 (2012)
- 김희정, "Investigation of Toxin Gene Diversity, Molecular Epidemiology, and Antimicrobial Resistance of Clostridium difficile Isolated from 12 Hospitals in South Korea", Annals of Laboratory Medicine, 30(5), pp.491~497 (2010), 대한진단검사의학회
- Carroll KC, "Biology of Clostridium difficile:implications for epidemiology and diagnosis", Annu RevMicrobiol, 65, pp.501~521 (2011)
- Geric B, "Binary toxin-producing,large clostridial toxin-negative Clostridium difficilestrains are enterotoxic but do not cause disease inhamsters", J Infect Dis, 193, pp.1143~1150 (2006)
- Schwan C, "Clostridium difficiletoxin CDT induces formation of microtubule-based protrusionsand increases adherence of bacteria", PLoS Pathog, 5, pp.e1000626~ (2009)
- Kelly CP, "Clostridium difficile--more difficultthan ever", N Engl J Med, 359, pp.1932~1940 (2008)
- Warny M, "Toxin production by anemerging strain of Clostridium difficile associated withoutbreaks of severe disease in North America and Europe", Lancet, 366, pp.1079~1084 (2005)
- McDonald LC, "An epidemic,toxin gene-variant strain of Clostridium difficile", N Engl J Med, 353, pp.2433~2441 (2005)
- 태정현, "The First Case of Antibiotic-associated Colitis by Clostridium difficile PCR Ribotype 027 in Korea", Journal of Korean Medical Science, 24(3), pp.520~524 (2009), 대한의학회
- 김지은, "Epidemiology and Clinical Characteristics of Clostridium difficile Infection in a Korean Tertiary Hospital", Journal of Korean Medical Science, 26(10), pp.1258~1264 (2011), 대한의학회
- Ferguson MK, "The rationale for developing scoring systemsfor clinical practice", Thorac Surg Clin, 17, pp.343~351 (2007)
- "World Health Organisation. The anatomicaltherapeutic chemical (ATC) and defined daily dosing(DDD) system index 2010" (2010)[URL]
- Zar FA, "A comparisonof vancomycin and metronidazole for the treatmentof Clostridium difficile-associated diarrhea, stratifiedby disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
- Gerding DN, "Treatment of Clostridiumdifficile infection", Clin Infect Dis, 46(1), pp.S32~S42 (2008)
- 정혜숙, "Clostridium difficile 연관 설사에 대한 metronidazole의 치료효과", 대한내과학회지, 72(6), pp.639~646 (2007), 대한내과학회
- Barbut F, "Epidemiology of recurrences or reinfectionsof Clostridium difficile-associated diarrhea", J Clin Microbiol, 38, pp.2386~2388 (2000)
- Seo MR, "Multiplex PCRmethod for detection of Clostridium difficile tcdA, tcdBand binary toxin genes", 2012 Annual Meeting of the KoreanSociety of Infectious Disease and the Korean Societyfor Chemotherapy, 1-2, pp.17~ (2012)
- Kim J, "Association between PCRribotypes and antimicrobial susceptibility among Clostridiumdifficile isolates from healthcare-associated infectionsin South Korea", Int J Antimicrob Agents, 40, pp.24~29 (2012)
- 김희정, "Emergence of Clostridium difficile Ribotype 027 in Korea", Annals of Laboratory Medicine, 31(3), pp.191~196 (2011), 대한진단검사의학회
- Bauer MP, "ECDIS Study Group. Clostridium difficile infectionin Europe: a hospital-based survey", Lancet, 377, pp.63~73 (2011)
- Bacci S, "Binary toxinand death after Clostridium difficile infection", Emerg InfectDis, 17, pp.976~982 (2011)
- Barbut F, "Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specificADP-ribosyltransferase)-producing strains", J MedMicrobiol, 54, pp.181~185 (2005)
- Barbut F, "Clinical features of Clostridium difficile-associated infections and molecular characterizationof strains: results of a retrospective study, 2000-2004", Infect Control Hosp Epidemiol, 28, pp.131~139 (2007)
- Walk ST, "Clostridium difficile ribotype does not predict severeinfection", Clin Infect Dis, 55, pp.1661~1668 (2012)
- Jobe BA, "Clostridium difficile colitis: an increasing hospital-acquired illness", Am J Surg, 169, pp.480~483 (1995)
- Lyytikainen O, "Hospitalizations anddeaths associated with Clostridium difficile infection,Finland, 1996-2004", Emerg Infect Dis, 15, pp.761~765 (2009)
- Rubin MS, "Severe Clostridiumdifficile colitis", Dis Colon Rectum, 38, pp.350~354 (1995)